Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBN-2397 in advanced solid tumors
NCT04053673Phase 1Unknown
- Sponsor
- Ribon Therapeutics
- Start
- Aug 2019
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of atamparib in solid tumor, lung squamous cell carcinoma (LSCC), head and neck squamous cell carcinoma (HNSCC) and 1 more, sponsored by Ribon Therapeutics. Primary endpoints: Maximum Tolerated Dose at 21 days and Recommended Phase 2 Dose at 21 days. Status: unknown.
02
Drugs
atamparib
03
Conditions
solid tumorlung squamous cell carcinoma (LSCC)head and neck squamous cell carcinoma (HNSCC)breast cancer
Beyond the preview
Go deeper on NCT04053673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04053673.